Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, GA
White, CA
Witzig, TA
Stabin, MG
Spies, S
Silverman, DH
Raubitschek, A
Gordon, L
Emmanouilides, C
Janakiraman, N
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 1999年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
260
引用
收藏
页码：64P / 64P
页数：1
相关论文
共 50 条
  • [21] A phase I clinical study of 111In/90Y-2IT-BAD-Lym-1 for non-Hodgkin's lymphoma (NHL).
    O'Donnell, RT
    DeNardo, GL
    Shen, S
    Kukis, DL
    Yuan, A
    Goldstein, DS
    Wun, T
    DeNardo, SJ
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 216P - 216P
  • [22] Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report
    Borghaei, Hossein
    Schilder, Russell J.
    Litwin, Samuel
    Millenson, Michael
    Cohen, Adam D.
    Thibodeau, Linda
    Smith, Mitchell R.
    BLOOD, 2012, 120 (21)
  • [23] Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL):: Initial phase I/II study results
    Weiden, PL
    Breitz, HB
    Press, O
    Appelbaum, JW
    Bryan, JK
    Gaffigan, S
    Stone, D
    Axworthy, D
    Fisher, D
    Reno, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (01) : 15 - 29
  • [24] Review of single agent IDEC-C2B8 safety and efficacy results in low-grade or follicular non-hodgkin's lymphoma (NHL)
    White, CA
    GrilloLopez, AJ
    Maloney, D
    Bodkin, D
    Czuczman, M
    McLaughlin, P
    Cabanillas, F
    Saven, A
    Saleh, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 91 - 91
  • [25] Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma.
    Wiseman, GA
    Witzig, TE
    Dunn, WL
    Chin, P
    Salinger, AM
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 1062 - 1062
  • [26] Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report of a phase II trial
    Younes, A
    Ayoub, JP
    Sarris, A
    Hagemeister, F
    North, L
    Pate, O
    McLaughlin, P
    Rodriguez, MA
    Romaguera, J
    Kurzrock, R
    Preti, A
    Bachier, C
    Smith, T
    Cabanillas, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (02) : 328 - 332
  • [27] A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL).
    Timmerman, J
    Czerwinski, D
    van Beckhoven, A
    Vose, J
    Ingolia, D
    Kunkel, L
    Denney, D
    Levy, R
    BLOOD, 2000, 96 (11) : 578A - +
  • [28] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [29] A ramdomized controlled trial of Zevalin™ radioimmunotherapy (RIT) for B-cell non-Hodgkin's lymphoma (NHL):: Biodistribution and dosimetry results.
    Wiseman, GA
    Sparks, RB
    Leigh, BR
    Erwin, WD
    Podoloff, DA
    Bartlett, NL
    Kornmehl, E
    Lomonica, D
    Dunn, WL
    Rosenberg, J
    Grillo-Lopez, AJ
    White, CA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 29P - 29P
  • [30] Phase II trial of fludarabine alternating with interferon (IFN)alpha 2B in low grade non-Hodgkin's lymphoma (NHL)
    Smith, MR
    Boyd, RL
    Minnitti, C
    Clyde, J
    Hoessly, MC
    Cornfeld, M
    Yeslow, G
    Halbherr, T
    Rogatko, A
    Schilder, RJ
    Young, RC
    Millenson, MM
    BLOOD, 1997, 90 (10) : 861 - 861
12345